Developer docs
API playgroundTry for free, no card

Search company profiles

Synthego

Full company profile

uuid0000gm2

Namestring
Synthego
Legal namestring
Synthego Holdings LLC
Websiteurl
synthego.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Synthego is a genome engineering tools company that designs, manufactures, and supplies synthetic sgRNA and engineered CRISPR nucleases to therapeutic developers, academic researchers, and industrial biotechnology customers. Its core product lines include synthetic sgRNA, proprietary nucleases such as eSpOT-ON (a high-fidelity SpCas9 reported to reduce off-target activity), hfCas12Max, AccuBase, and a growing catalog of GMP-grade reagents (including GMP SpCas9) plus molecular biology enzymes (T7 RNA Polymerase, RNase Inhibitor) and high-performance molecular reagents. Manufacturing is supported by the HALO synthesis platform, which automates production and reportedly eliminates HPLC purification, enabling high-throughput sgRNA manufacturing at scale (2M+ gRNA units delivered, 200+ clinical batches, 14 INDs cleared to date).

The company operates a hybrid go-to-market model: direct e-commerce for research-use reagents to a long-tail customer base, distribution partnerships in 17+ countries, and enterprise/licensing agreements with therapeutic developers for proprietary nucleases (e.g., AstraZeneca for eSpOT-ON, Vita Therapeutics for hfCas12Max). Quality systems include cGMP, ISO 13485, and ISO 9001 certifications supporting clinical and regulated use. Following a Chapter 11 filing in May 2025, Synthego was acquired by Perceptive Advisors in July 2025 and has subsequently pivoted toward diagnostic reagents (biotechrabbit partnership, January 2026) and additional nuclease product launches (AccuBase with Kactus, November 2025). The company is headquartered in Redwood City, California, was founded in 2012 by Paul and Michael Dabrowski, and operates with approximately 101–250 employees.

Short descriptiontext

Synthego is a Redwood City-based genome engineering tools company that supplies synthetic sgRNA, proprietary engineered nucleases (eSpOT-ON, hfCas12Max, AccuBase), and GMP-grade reagents to therapeutic developers, academic labs, and industrial biotech customers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CRISPR gene editing, synthetic guide RNA, engineered nucleases, GMP manufacturing services, molecular diagnostics reagents
Industry4 codes
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
CRISPR Gene Editing Reagents
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1CRISPR Research Products
TypeOne Time License
Description

Sale of synthetic sgRNA, nucleases (SpCas9, hfCas12Max, eSpOT-ON), and base editors for research use applications. Products sold directly through e-commerce and distributors.

synthego.com
2GMP Manufacturing Services
TypeTransaction Fee
Description

cGMP manufacturing of sgRNA and nucleases for clinical and therapeutic applications with regulatory documentation support including Drug Master Files for IND submissions

synthego.com
3Molecular Diagnostics Reagents
TypeOne Time License
Description

Entry into molecular and clinical diagnostic reagents market including isothermal amplification (RPA, LAMP), PCR/RT enzymes, IVT enzymes, and sample preparation products

synthego.com
4Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary nucleases (hfCas12Max, eSpOT-ON) to pharmaceutical and biotech companies for therapeutic development with sublicensing rights

synthego.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Research Use Only (RUO) products available for online purchase with standard pricing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Standard list pricing for synthetic sgRNA and nucleases, available through website account

synthego.com
2GMP/Clinical grade products require quotation and custom manufacturing agreements
ModelTransaction based/ take rateBilling cadenceMulti-year contract
Notes

50% reservation fee required to secure manufacturing slot, with remaining balance due upon shipment. Quote-based pricing for custom GMP products.

synthego.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Synthego manufactures and sells CRISPR-based genome engineering products including synthetic single guide RNAs (sgRNAs), engineered nucleases (SpCas9, hfCas12Max, eSpOT-ON, AccuBase), and molecular biology reagents such as IVT enzymes and isothermal amplification kits. The company also provides cGMP manufacturing of clinical-grade CRISPR reagents and regulatory expertise services supporting IND submissions for cell and gene therapy developers. Offerings span Research Use Only products sold through e-commerce, GMP-grade products for therapeutic development, and molecular diagnostics reagents manufactured in partnership with biotechrabbit GmbH.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 14 INDs cleared using Synthego GMP products
+5 more records
Product overview1 text field

Synthego offers a comprehensive CRISPR and molecular biology portfolio organized across three product pillars: (1) CRISPR Gene Editing products including Research Use Only synthetic sgRNAs, engineered nucleases (eSpOT-ON, hfCas12Max), and the AccuBase cytosine base editor; (2) GMP Manufacturing solutions comprising GMP-grade sgRNA, GMP SpCas9, and GMP AccuBase for clinical cell and gene therapy development; and (3) Molecular Biology products spanning IVT enzymes (T7 Polymerase, RNase Inhibitor), isothermal amplification reagents (RPA), PCR/RT enzymes, and cell-free protein expression kits. The company supports these products with software tools including the CRISPR Design Tool for guide RNA design and ICE CRISPR Analysis Tool for editing validation, plus Regulatory Expertise services for IND submissions. Synthego has supported over 14 IND clearances and completed more than 200 clinical sgRNA batches.

Product and service20 records
1Research sgRNA (Synthetic Guide RNA)
CategoryCRISPR Gene Editing Reagents
Description

Chemically modified synthetic single guide RNAs for CRISPR-Cas9 genome editing experiments, designed for high purity and editing efficiency without requiring HPLC purification. Sold directly through e-commerce for life science researchers.

2eSpOT-ON Nuclease Protein
CategoryEngineered Nuclease
Description

Engineered high-fidelity Cas9 variant (ePsCas9) delivered as recombinant protein, designed for therapeutic gene editing with high on-target activity and low off-target effects. Licensed from AstraZeneca.

3eSpOT-ON Nuclease mRNA
CategoryEngineered Nuclease
Description

Engineered high-fidelity Cas9 variant delivered in mRNA format for expression in cells, supporting cell and gene therapy development with high fidelity and low off-target effects. Licensed from AstraZeneca.

4hfCas12Max Nuclease Protein
CategoryEngineered Nuclease
Description

High-fidelity Cas12 nuclease variant engineered for therapeutic gene editing, offering broad PAM recognition, high specificity, small size, and effectiveness across various cell types. Exclusively licensed from Huidagene.

5hfCas12Max Nuclease mRNA
CategoryEngineered Nuclease
Description

High-fidelity Cas12 nuclease variant delivered as mRNA for therapeutic gene editing applications requiring precision and flexibility.

6AccuBase Cytosine Base Editor
CategoryCRISPR Base Editor
Description

Engineered cytosine base editor (CBE) that eliminates double-strand breaks for safer CRISPR-based therapeutics, available in research-grade and GMP formats with near-zero off-target effects. Developed in partnership with Kactus Biosciences and Base Therapeutics.

7Research SpCas9 Protein
CategoryEngineered Nuclease
Description

Wild-type SpCas9 nuclease protein for CRISPR-Cas9 genome editing research applications.

8Research SpCas9 mRNA
CategoryEngineered Nuclease
Description

SpCas9 nuclease delivered as mRNA for research genome editing applications.

9GMP sgRNA
CategoryGMP CRISPR Reagents
Description

Good Manufacturing Practice-grade single guide RNAs for use in CRISPR-based cell and gene therapies, with regulatory support and quality documentation including Drug Master Files for IND submissions.

10GMP SpCas9
CategoryGMP CRISPR Reagents
Description

GMP-grade SpCas9 nuclease produced under certified cGMP manufacturing standards, designed for clinical research and therapeutic development.

11GMP AccuBase
CategoryGMP CRISPR Reagents
Description

GMP-grade cytosine base editor for clinical cell and gene therapy applications requiring high-fidelity base editing.

12Custom Nuclease Manufacturing
CategoryCustom Manufacturing Service
Description

Custom CRISPR gene editors available in mRNA or protein formats for clinical applications, manufactured under GMP conditions.

13T7 RNA Polymerase
CategoryMolecular Biology Reagent
Description

Engineered T7 RNA polymerase for in vitro transcription applications, generating high yields of RNA for mRNA therapeutics and CRISPR guide RNA synthesis.

14RNase Inhibitor
CategoryMolecular Biology Reagent
Description

RNase inhibitor enzyme for in vitro transcription and RNA research applications, protecting RNA from degradation during synthesis.

15RPA Endpoint Kit
CategoryMolecular Diagnostics Reagent
Description

Recombinase Polymerase Amplification kit for reliable DNA amplification with endpoint detection, delivering results in minutes for molecular diagnostics applications.

16Isothermal Amplification Products
CategoryMolecular Diagnostics Reagent
Description

Reagents for isothermal nucleic acid amplification methods including RPA and LAMP, designed for molecular diagnostics workflows requiring rapid, field-deployable testing.

17PCR & RT Enzymes & Products
CategoryMolecular Diagnostics Reagent
Description

PCR and reverse transcription enzymes and products for molecular biology and clinical diagnostics applications.

18Cell-Free Protein Expression Kit
CategoryMolecular Biology Reagent
Description

Rapid, high-yield protein production in a controlled, scalable system without the need for live cells, for research and therapeutic development applications.

19Sample Preparation & Processing
CategoryMolecular Diagnostics Reagent
Description

Reagents and products for nucleic acid preparation and processing for molecular diagnostics applications.

20Regulatory Expertise Services
CategoryRegulatory Service
Description

Regulatory guidance and expert support for CRISPR-based therapies, including IND submission assistance, strategic regulatory advice, and proactive regulatory intelligence.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Collaboration for manufacturing molecular biology and clinical diagnostic reagents. biotechrabbit manufactures enzymes for Synthego's diagnostic reagent portfolio including products for nucleic acid amplification, detection, and quality control under ISO 13485 and ISO 9001 quality systems.

2Kactus Biosciences
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-26
Description

Partnership to commercialize AccuBase, a Cas-embedded cytosine base editor with near-zero off-target effects. Kactus manufactures the product while Synthego commercializes and distributes. AccuBase embeds deaminase enzymes within Cas9 protein to reduce off-target activity while maintaining high on-target efficiency.

synthego.com
3Vita Therapeutics
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-04-08
Description

Strategic nonexclusive licensing agreement granting Vita Therapeutics access to Synthego's high-fidelity hfCas12Max CRISPR system for therapeutic applications including preclinical and clinical programs for neuromuscular disorders. Synthego's goal is to reduce upfront licensing fees to make CRISPR solutions more accessible.

synthego.com
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-01-13
Description

Strategic licensing agreement where Synthego received exclusive global rights to manufacture and distribute AstraZeneca's CRISPR gene editing enzyme eSpOT-ON, including exclusive commercialization and sublicensing rights for therapeutic and commercial use. Partnership combines AstraZeneca's nuclease technology with Synthego's gRNA and regulatory expertise.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Referral partnership for Engineered Cells, Gene Knockout Kits, and Arrayed Screening Libraries. Synthego directs customers to EditCo for these specific products while maintaining separate operations and support.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1IDT (Integrated DNA Technologies)
TypeDirect peer
Description

IDT is a leading manufacturer of custom oligonucleotides including sgRNAs and CRISPR reagents, directly competing with Synthego's research and GMP sgRNA lines across academic, biotech, and therapeutic customers globally.

TypeDirect peer
Description

EditCo is a direct competitor in synthetic sgRNAs and engineered cells, and is also a Synthego referral partner for GKO kits and arrayed screening libraries — overlapping on CRISPR reagent manufacturing and gene knockout services.

TypeDirect peer
Description

Twist Bioscience manufactures synthetic DNA and sgRNA libraries at scale using a silicon-based DNA synthesis platform, competing directly with Synthego's synthetic sgRNA and arrayed library offerings for research and functional genomics.

TypeBroad incumbent
Description

Thermo Fisher offers CRISPR reagents through its GeneArt and other product lines and bundles them into broader gene editing and cell therapy workflows, competing with Synthego as a broad incumbent across research and GMP cell therapy manufacturing.

TypeDirect peer
Description

GenScript provides custom gene synthesis, sgRNA manufacturing, and CRISPR-related services through its life-science reagents business, overlapping with Synthego's research and cell therapy reagent offerings.

TypeBroad incumbent
Description

Horizon (now part of Revvity) provides CRISPR reagents and cell line engineering services through its gene editing portfolio, competing with Synthego's offerings within a broader life sciences and diagnostics portfolio.

TypeDirect peer
Description

Aldevron manufactures GMP-grade plasmids, proteins, and nucleic acids used in cell and gene therapy manufacturing, overlapping with Synthego's GMP sgRNA and nuclease manufacturing business for clinical-stage customers.

TypeEmerging player
Description

Beam is a clinical-stage developer of base editing therapeutics — directly competing with AccuBase as a cytosine base editing technology and a potential customer/partner for Synthego's nuclease and base editor reagents.

TypeEmerging player
Description

Intellia develops in vivo CRISPR/Cas9 therapeutics and is both a potential customer for Synthego's GMP CRISPR reagents and a competing technology platform pushing the frontier of therapeutic gene editing.

TypeEmerging player
Description

Codexis engineers proteins and enzymes for therapeutic and molecular biology applications, with overlap on Synthego's engineered nuclease (eSpOT-ON, hfCas12Max) and IVT enzyme portfolios, particularly in protein engineering for high-fidelity variants.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synthego

CRISPR Gene Editing Reagentssynthego.com

Synthego is a Redwood City-based genome engineering tools company that supplies synthetic sgRNA, proprietary engineered nucleases (eSpOT-ON, hfCas12Max, AccuBase), and GMP-grade reagents to therapeutic developers, academic labs, and industrial biotech customers worldwide.

What Synthego does

Synthego is a genome engineering tools company that designs, manufactures, and supplies synthetic sgRNA and engineered CRISPR nucleases to therapeutic developers, academic researchers, and industrial biotechnology customers. Its core product lines include synthetic sgRNA, proprietary nucleases such as eSpOT-ON (a high-fidelity SpCas9 reported to reduce off-target activity), hfCas12Max, AccuBase, and a growing catalog of GMP-grade reagents (including GMP SpCas9) plus molecular biology enzymes (T7 RNA Polymerase, RNase Inhibitor) and high-performance molecular reagents. Manufacturing is supported by the HALO synthesis platform, which automates production and reportedly eliminates HPLC purification, enabling high-throughput sgRNA manufacturing at scale (2M+ gRNA units delivered, 200+ clinical batches, 14 INDs cleared to date).

The company operates a hybrid go-to-market model: direct e-commerce for research-use reagents to a long-tail customer base, distribution partnerships in 17+ countries, and enterprise/licensing agreements with therapeutic developers for proprietary nucleases (e.g., AstraZeneca for eSpOT-ON, Vita Therapeutics for hfCas12Max). Quality systems include cGMP, ISO 13485, and ISO 9001 certifications supporting clinical and regulated use. Following a Chapter 11 filing in May 2025, Synthego was acquired by Perceptive Advisors in July 2025 and has subsequently pivoted toward diagnostic reagents (biotechrabbit partnership, January 2026) and additional nuclease product launches (AccuBase with Kactus, November 2025). The company is headquartered in Redwood City, California, was founded in 2012 by Paul and Michael Dabrowski, and operates with approximately 101–250 employees.

Synthego firmographics

Firmographics
Name
Synthego
Legal name
Synthego Holdings LLC
Website
https://synthego.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Synthego is a Redwood City-based genome engineering tools company that supplies synthetic sgRNA, proprietary engineered nucleases (eSpOT-ON, hfCas12Max, AccuBase), and GMP-grade reagents to therapeutic developers, academic labs, and industrial biotech customers worldwide.
Ownership category
akta.pro rank

Synthego industry classification

Industry
Product category
CRISPR Gene Editing Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAKAE
Plasmid DNA & mRNA Manufacturing Services
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • CRISPR gene editing
  • Synthetic guide RNA
  • Engineered nucleases
  • GMP manufacturing services
  • Molecular diagnostics reagents

Where Synthego is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Synthego business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. CRISPR Research Products: Sale of synthetic sgRNA, nucleases (SpCas9, hfCas12Max, eSpOT-ON), and base editors for research use applications. Products sold directly through e-commerce and distributors.
  2. GMP Manufacturing Services: cGMP manufacturing of sgRNA and nucleases for clinical and therapeutic applications with regulatory documentation support including Drug Master Files for IND submissions
  3. Molecular Diagnostics Reagents: Entry into molecular and clinical diagnostic reagents market including isothermal amplification (RPA, LAMP), PCR/RT enzymes, IVT enzymes, and sample preparation products
  4. Technology Licensing: Licensing of proprietary nucleases (hfCas12Max, eSpOT-ON) to pharmaceutical and biotech companies for therapeutic development with sublicensing rights

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goResearch Use Only (RUO) products available for online purchase with standard pricing
Transaction based/ take rateMulti-year contractGMP/Clinical grade products require quotation and custom manufacturing agreements

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Synthego product offering

Product offering

Core offering

Synthego manufactures and sells CRISPR-based genome engineering products including synthetic single guide RNAs (sgRNAs), engineered nucleases (SpCas9, hfCas12Max, eSpOT-ON, AccuBase), and molecular biology reagents such as IVT enzymes and isothermal amplification kits. The company also provides cGMP manufacturing of clinical-grade CRISPR reagents and regulatory expertise services supporting IND submissions for cell and gene therapy developers. Offerings span Research Use Only products sold through e-commerce, GMP-grade products for therapeutic development, and molecular diagnostics reagents manufactured in partnership with biotechrabbit GmbH.

Product overview

Synthego offers a comprehensive CRISPR and molecular biology portfolio organized across three product pillars: (1) CRISPR Gene Editing products including Research Use Only synthetic sgRNAs, engineered nucleases (eSpOT-ON, hfCas12Max), and the AccuBase cytosine base editor; (2) GMP Manufacturing solutions comprising GMP-grade sgRNA, GMP SpCas9, and GMP AccuBase for clinical cell and gene therapy development; and (3) Molecular Biology products spanning IVT enzymes (T7 Polymerase, RNase Inhibitor), isothermal amplification reagents (RPA), PCR/RT enzymes, and cell-free protein expression kits. The company supports these products with software tools including the CRISPR Design Tool for guide RNA design and ICE CRISPR Analysis Tool for editing validation, plus Regulatory Expertise services for IND submissions. Synthego has supported over 14 IND clearances and completed more than 200 clinical sgRNA batches.

Differentiator

Problem solved

Functional benefit

Products and services

  • Research sgRNA (Synthetic Guide RNA) Chemically modified synthetic single guide RNAs for CRISPR-Cas9 genome editing experiments, designed for high purity and editing efficiency without requiring HPLC purification. Sold directly through e-commerce for life science researchers.
  • eSpOT-ON Nuclease Protein Engineered high-fidelity Cas9 variant (ePsCas9) delivered as recombinant protein, designed for therapeutic gene editing with high on-target activity and low off-target effects. Licensed from AstraZeneca.
  • eSpOT-ON Nuclease mRNA Engineered high-fidelity Cas9 variant delivered in mRNA format for expression in cells, supporting cell and gene therapy development with high fidelity and low off-target effects. Licensed from AstraZeneca.
  • hfCas12Max Nuclease Protein High-fidelity Cas12 nuclease variant engineered for therapeutic gene editing, offering broad PAM recognition, high specificity, small size, and effectiveness across various cell types. Exclusively licensed from Huidagene.
  • hfCas12Max Nuclease mRNA High-fidelity Cas12 nuclease variant delivered as mRNA for therapeutic gene editing applications requiring precision and flexibility.
  • AccuBase Cytosine Base Editor Engineered cytosine base editor (CBE) that eliminates double-strand breaks for safer CRISPR-based therapeutics, available in research-grade and GMP formats with near-zero off-target effects. Developed in partnership with Kactus Biosciences and Base Therapeutics.
  • Research SpCas9 Protein Wild-type SpCas9 nuclease protein for CRISPR-Cas9 genome editing research applications.
  • Research SpCas9 mRNA SpCas9 nuclease delivered as mRNA for research genome editing applications.
  • GMP sgRNA Good Manufacturing Practice-grade single guide RNAs for use in CRISPR-based cell and gene therapies, with regulatory support and quality documentation including Drug Master Files for IND submissions.
  • GMP SpCas9 GMP-grade SpCas9 nuclease produced under certified cGMP manufacturing standards, designed for clinical research and therapeutic development.
  • GMP AccuBase GMP-grade cytosine base editor for clinical cell and gene therapy applications requiring high-fidelity base editing.
  • Custom Nuclease Manufacturing Custom CRISPR gene editors available in mRNA or protein formats for clinical applications, manufactured under GMP conditions.
  • T7 RNA Polymerase Engineered T7 RNA polymerase for in vitro transcription applications, generating high yields of RNA for mRNA therapeutics and CRISPR guide RNA synthesis.
  • RNase Inhibitor RNase inhibitor enzyme for in vitro transcription and RNA research applications, protecting RNA from degradation during synthesis.
  • RPA Endpoint Kit Recombinase Polymerase Amplification kit for reliable DNA amplification with endpoint detection, delivering results in minutes for molecular diagnostics applications.
  • Isothermal Amplification Products Reagents for isothermal nucleic acid amplification methods including RPA and LAMP, designed for molecular diagnostics workflows requiring rapid, field-deployable testing.
  • PCR & RT Enzymes & Products PCR and reverse transcription enzymes and products for molecular biology and clinical diagnostics applications.
  • Cell-Free Protein Expression Kit Rapid, high-yield protein production in a controlled, scalable system without the need for live cells, for research and therapeutic development applications.
  • Sample Preparation & Processing Reagents and products for nucleic acid preparation and processing for molecular diagnostics applications.
  • Regulatory Expertise Services Regulatory guidance and expert support for CRISPR-based therapies, including IND submission assistance, strategic regulatory advice, and proactive regulatory intelligence.

Quantifiable outcome

  • 14 INDs cleared using Synthego GMP products
  • +5 more outcomes

Companies that use Synthego

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Synthego technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Synthego partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major, flagship and minor.

  • biotechrabbit GmbHmajorStrategic or Co-development Partner · 13 January 2026Collaboration for manufacturing molecular biology and clinical diagnostic reagents. biotechrabbit manufactures enzymes for Synthego's diagnostic reagent portfolio including products for nucleic acid amplification, detection, and quality control under ISO 13485 and ISO 9001 quality systems.
  • Kactus BiosciencesmajorStrategic or Co-development Partner · 26 November 2025Partnership to commercialize AccuBase, a Cas-embedded cytosine base editor with near-zero off-target effects. Kactus manufactures the product while Synthego commercializes and distributes. AccuBase embeds deaminase enzymes within Cas9 protein to reduce off-target activity while maintaining high on-target efficiency.
  • Vita TherapeuticsmajorOEM/ Whitelabel/ Licensing Partner · 8 April 2025Strategic nonexclusive licensing agreement granting Vita Therapeutics access to Synthego's high-fidelity hfCas12Max CRISPR system for therapeutic applications including preclinical and clinical programs for neuromuscular disorders. Synthego's goal is to reduce upfront licensing fees to make CRISPR solutions more accessible.
  • AstraZenecaflagshipOEM/ Whitelabel/ Licensing Partner · 13 January 2025Strategic licensing agreement where Synthego received exclusive global rights to manufacture and distribute AstraZeneca's CRISPR gene editing enzyme eSpOT-ON, including exclusive commercialization and sublicensing rights for therapeutic and commercial use. Partnership combines AstraZeneca's nuclease technology with Synthego's gRNA and regulatory expertise.
  • EditCominorChannel Partner/ Reseller/ DistributorReferral partnership for Engineered Cells, Gene Knockout Kits, and Arrayed Screening Libraries. Synthego directs customers to EditCo for these specific products while maintaining separate operations and support.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Synthego competitors and assessment

Company assessment

Direct peers

  • IDT (Integrated DNA Technologies): IDT is a leading manufacturer of custom oligonucleotides including sgRNAs and CRISPR reagents, directly competing with Synthego's research and GMP sgRNA lines across academic, biotech, and therapeutic customers globally.
  • EditCo Bio: EditCo is a direct competitor in synthetic sgRNAs and engineered cells, and is also a Synthego referral partner for GKO kits and arrayed screening libraries — overlapping on CRISPR reagent manufacturing and gene knockout services.
  • Twist Bioscience: Twist Bioscience manufactures synthetic DNA and sgRNA libraries at scale using a silicon-based DNA synthesis platform, competing directly with Synthego's synthetic sgRNA and arrayed library offerings for research and functional genomics.
  • GenScript: GenScript provides custom gene synthesis, sgRNA manufacturing, and CRISPR-related services through its life-science reagents business, overlapping with Synthego's research and cell therapy reagent offerings.
  • Aldevron: Aldevron manufactures GMP-grade plasmids, proteins, and nucleic acids used in cell and gene therapy manufacturing, overlapping with Synthego's GMP sgRNA and nuclease manufacturing business for clinical-stage customers.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher offers CRISPR reagents through its GeneArt and other product lines and bundles them into broader gene editing and cell therapy workflows, competing with Synthego as a broad incumbent across research and GMP cell therapy manufacturing.
  • Horizon Discovery (Revvity): Horizon (now part of Revvity) provides CRISPR reagents and cell line engineering services through its gene editing portfolio, competing with Synthego's offerings within a broader life sciences and diagnostics portfolio.

Emerging players

  • Beam Therapeutics: Beam is a clinical-stage developer of base editing therapeutics — directly competing with AccuBase as a cytosine base editing technology and a potential customer/partner for Synthego's nuclease and base editor reagents.
  • Intellia Therapeutics: Intellia develops in vivo CRISPR/Cas9 therapeutics and is both a potential customer for Synthego's GMP CRISPR reagents and a competing technology platform pushing the frontier of therapeutic gene editing.
  • Codexis: Codexis engineers proteins and enzymes for therapeutic and molecular biology applications, with overlap on Synthego's engineered nuclease (eSpOT-ON, hfCas12Max) and IVT enzyme portfolios, particularly in protein engineering for high-fidelity variants.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Synthego social profiles

Digital presence

Synthego compliance and trust

Trust signal

Compliance3 records

Synthego financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synthego leadership team

Management profile

Number of profiles

Profiles7 records

Synthego funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synthego M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synthego

What does Synthego do?

Synthego manufactures and sells CRISPR-based genome engineering products including synthetic single guide RNAs (sgRNAs), engineered nucleases (SpCas9, hfCas12Max, eSpOT-ON, AccuBase), and molecular biology reagents such as IVT enzymes and isothermal amplification kits. The company also provides cGMP manufacturing of clinical-grade CRISPR reagents and regulatory expertise services supporting IND submissions for cell and gene therapy developers. Offerings span Research Use Only products sold through e-commerce, GMP-grade products for therapeutic development, and molecular diagnostics reagents manufactured in partnership with biotechrabbit GmbH.

Is Synthego a public or private company?

Synthego is a private company. It is classified as private equity controlled and is currently operating.

When was Synthego founded?

Synthego was founded in 2012. It employs 101 to 250 people.

Where is Synthego based?

Synthego is headquartered in Redwood City, United States, in the North America region.

How does Synthego make money?

Four revenue lines are on record. CRISPR Research Products are the primary driver. The others are GMP Manufacturing Services, molecular Diagnostics Reagents and technology Licensing.

Who are Synthego's main competitors?

Direct peers on record are IDT (Integrated DNA Technologies), EditCo Bio, Twist Bioscience, GenScript and Aldevron. Broad incumbents are Thermo Fisher Scientific and Horizon Discovery (Revvity). Emerging players are Beam Therapeutics, Intellia Therapeutics and Codexis.

Does Synthego have an API?

No public API is recorded for Synthego.

What industry is Synthego in?

Synthego's product category is CRISPR Gene Editing Reagents. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq), with a secondary code of HLAAAKAE, Plasmid DNA & mRNA Manufacturing Services. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Grand View ResearchgRNA Market Size, Share And Growth Report, 2026-2033Grand View Research published a market report projecting the global gRNA market to grow from USD 677.2 million in 2025 to USD 2,658.9 million by 2033, driven by expanding CRISPR applications in therapeutics and research. The report highlights North America as the dominant region and identifies key industry participants such as Thermo Fisher Scientific, Merck KGaA, and Synthego through recent strategic activities like acquisitions and product portfolio expansions.SynthegoThe Rise of CRISPR DiagnosticsCRISPR diagnostics use programmable guide RNAs and Cas enzymes to detect genetic targets, offering speed and flexibility over traditional PCR. Synthego provides synthetic gRNAs and RPA kits to support assay development. The technology has seen real-world impact in pandemic response and food safety.SynthegoCRISPR Delivery Methods for Scalable Gene EditingThis article examines the strategic considerations for selecting CRISPR delivery methods as gene editing programs progress from discovery to clinical development, contrasting adeno-associated virus (AAV) vectors with non-viral approaches such as ribonucleoprotein (RNP) and mRNA delivery. It details how AAV production relies on complex biological manufacturing processes that create scalability challenges, whereas non-viral methods offer modular, more predictable scaling through standardized biochemical production. The piece, published by Synthego, positions protein and mRNA delivery as complementary pathways within non-viral approaches, emphasizing flexibility and the ability to adapt delivery strategies as programs advance through development stages.GenomeWebUS Supreme Court Denies Agilent Request to Review CRISPR Patent Invalidation in Synthego IP BattleThe US Supreme Court denied Agilent Technologies' petition for a writ of certiorari to review the invalidation of two CRISPR-related patents, effectively ending a multi-year legal battle with gene editing firm Synthego. The decision leaves intact the June 2025 Federal Circuit ruling that upheld PTAB's determination that Agilent's US Patent Nos. 10,337,001 and 10,900,034 covering chemical modifications of guide RNAs used in CRISPR-Cas gene editing contained unenforceable claims. Synthego initiated the inter partes review challenge in January 2022 after preemptively suing Agilent, and the company stated the invalidation removes a significant barrier to innovation in CRISPR-enabled research and therapeutics.PR NewswireSynthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR PatentsSynthego announced that the U.S. Supreme Court denied Agilent Technologies' petition for a writ of certiorari, finalizing the invalidation of two Agilent CRISPR-related patents (U.S. Patent Nos. 10,337,001 and 10,900,034) directed at chemical modifications of guide RNAs used in CRISPR-Cas gene editing. The Supreme Court's decision upholds the June 2025 ruling by the U.S. Court of Appeals for the Federal Circuit, which affirmed an earlier Patent Trial and Appeal Board decision that all claims of the patents were unpatentable. Synthego CEO Craig Christianson stated that this resolution clears a significant barrier to the use of essential gRNA modifications, enabling continued innovation in CRISPR-enabled research and therapeutics.LinkedInSynthegoSynthego is a biotechnology company specializing in CRISPR solutions for life science research and therapeutics, headquartered in Menlo Park, California. The company aims to accelerate research and development in gene editing for improved human health.SynthegoRPA or LAMP: Which Isothermal Amplification Method Wins?- SynthegoSynthego published a technical guide comparing two isothermal nucleic acid amplification methods—Recombinase Polymerase Amplification (RPA) and Loop-mediated Isothermal Amplification (LAMP)—for molecular diagnostic applications. The article details that RPA operates at near-physiological temperatures (37–42°C) with only two primers and delivers results in 10–20 minutes, while LAMP requires higher temperatures (60–65°C), four to six primers, and 30–60 minutes for amplification. Synthego positions RPA as the superior choice for point-of-care and field-deployable diagnostics, highlighting its simplified hardware requirements, lower energy demand, and compatibility with multiplexing and CRISPR-based detection systems.Synthego6 Common Molecular Diagnostics Bottlenecks (And Fixes)This article outlines six common workflow bottlenecks in molecular diagnostics—sample degradation and cross-contamination, inconsistent yields, PCR inhibitors, enzyme variability, reagent instability, and low sensitivity in isothermal assays—along with proposed solutions for each. The piece is authored by Synthego, a molecular reagents supplier, and promotes their product offerings as remedies for these technical challenges. The content serves as an educational resource for professionals in point-of-care testing and high-throughput clinical laboratories seeking to improve their molecular diagnostics workflows.